RxDoctor Payments Data

Rahwa Woldegiorgis

Acute Care · Woodbridge, VANPI 1689450983

Payments from drug & device makers

$2,414in general payments, 2019–2025

Across 112 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$378
  • Novartis$263
  • Cvrx, Inc.$238
  • E.r. Squibb & Sons, L.L.C.$226
  • Philips North America LLC$191
  • Pfizer$181
  • plus $937 from 14 others

What the payments were for

  • Food & beverage$2,414100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,414 in reported general payments places this provider in the 85th percentile of 599 acute care providers in Virginia.

See all acute care providers in Virginia

Medicare billing

Part B allowed, 2024
$37,849
Medicare patients
377
Services billed
500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$94,528
EntrestoSacubitril/Valsartan39$45,254
XareltoRivaroxaban12$17,090
Dofetilide18$8,588
Amiodarone Hcl53$1,780
Flecainide Acetate35$1,574
Atorvastatin Calcium43$550
Rosuvastatin Calcium33$536
Metoprolol Succinate39$416
Furosemide48$339
Carvedilol42$270
Metoprolol Tartrate40$266
Amlodipine Besylate61$236
Losartan Potassium20$175
ClopidogrelClopidogrel Bisulfate25$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$181$94,52894 claims
NovartisEntresto$263$45,25439 claims
Johnson & JohnsonXarelto$43$17,09012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 599 acute care providers in Virginia.

Other acute care in Woodbridge

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →